GLP-1 Drugs in Kids: What Do We Really Know?
· fitness
The GLP-1 Dilemma: Weighing Benefits and Risks in Pediatric Treatment
The increasing use of GLP-1 drugs among children and teens has sparked a necessary conversation about their long-term effects, efficacy, and potential risks. While these medications have shown promise in addressing obesity and type 2 diabetes in adults, the pediatric population raises unique concerns that demand careful consideration.
Research suggests that GLP-1 prescriptions for children under 12 are on the rise, with a significant jump in usage over the past few years. A recent study found that nearly 0.6% of kids aged 8 to 11 with obesity but without diabetes were prescribed an off-label GLP-1 between 2019 and 2026. This trend is concerning, especially given the limited data on the long-term effects of these medications in children.
The American Academy of Pediatrics has begun recommending a more proactive approach to treating childhood obesity, including the use of GLP-1 drugs. However, other groups like the U.S. Preventive Services Task Force remain hesitant due to a lack of conclusive evidence. This disconnect highlights the need for further research and transparency regarding the safety and efficacy of these medications in pediatric populations.
Epidemiologist Sarah Messiah notes that while GLP-1s can be effective for kids, there are still many unknowns about their long-term effects. “We have very little information about what happens when a patient stops one of these therapies,” she explains. “Do they start another one? Do they stop because it’s too expensive? Do they stop because of side effects?”
Messiah’s concerns are echoed by others in the field, who warn that the rapid development and approval of new GLP-1-based medications for pediatric populations may outpace our understanding of their risks and benefits. “The field is moving so fast that it’s just really hard to keep up,” she says.
Several key questions must be addressed as we move forward. What are the potential long-term consequences of using GLP-1s in children? How do these medications interact with other treatments, such as bariatric surgery or lifestyle modifications? And what role should parental consent and involvement play in pediatric treatment decisions?
The increasing reliance on precision obesity care also raises important questions about the future of medication-based weight loss. Will we see a shift towards cycling or switching between different GLP-1s, or will we focus on finding the most effective single therapy for each patient? As new medications like tirzepatide and retatrutide emerge, how will they be integrated into pediatric treatment protocols?
Ultimately, the GLP-1 dilemma serves as a stark reminder of the need for continued research, transparency, and caution in pediatric treatment. While these medications hold promise for addressing childhood obesity and type 2 diabetes, we must prioritize careful consideration of their potential risks and benefits. Only through rigorous investigation can we ensure that our children receive the safest and most effective care possible.
The pediatric population demands a tailored approach to treatment, one that balances the need for effective medication with the imperative of protecting vulnerable young lives.
Reader Views
- TGThe Gym Desk · editorial
It's striking that while GLP-1 drugs are being hailed as a breakthrough in pediatric treatment, we're forgetting that these medications were initially developed for adults with type 2 diabetes and obesity. We're essentially repurposing treatments meant to manage chronic conditions without knowing how they'll interact with growing bodies or impact long-term health outcomes. The real question is: what's the exit strategy when kids no longer need GLP-1s? Will we see a cycle of perpetual treatment, with some children stuck on these medications for years due to convenience or parental compliance rather than medical necessity?
- CTCoach Tara M. · strength coach
We're putting kids on GLP-1s without doing our due diligence on long-term consequences. I'm not saying these meds are inherently bad, but we can't just extrapolate adult data to pediatric populations and hope for the best. We need to consider metabolic flexibility, not just weight loss. These children may still face insulin resistance and other underlying issues that GLP-1s won't fix on their own. It's time to think about comprehensive lifestyle programs instead of relying on quick fixes with unknown outcomes.
- DRDevon R. · former athlete
It's imperative that we acknowledge the elephant in the room: GLP-1s are not a magic bullet for pediatric obesity. We're talking about medications that alter gut hormones, which can have unpredictable effects on growing bodies. While short-term studies may show promise, we need to consider the long game – what happens when these kids grow up and stop taking the meds? Do they maintain weight loss or develop new health issues? The American Academy of Pediatrics is taking a proactive stance, but I worry that we're moving too fast without solid evidence.